Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts

Anne K Monroe; Matthew E Levy; Alan E Greenberg; Jeanne C Keruly; Richard D Moore; Michael A Horberg; Paige Kulie; Bernadine S Mohanraj; Princy N Kumar; Amanda D Castel; DC Cohort Executive Committee

doi:10.1093/ofid/ofab338

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts

Open Forum Infect Dis. 2021 Jul 27;8(8):ofab338. doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.

Collaborators

Affiliations

¹ The George Washington University, Washington, DC, USA.
² Westat, Rockville, Maryland, USA.
³ The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Kaiser Permanente Mid-Atlantic States, Rockville, Maryland, USA.
⁵ Georgetown University School of Medicine, Washington, DC, USA.

Abstract

Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons.

Keywords: HIV; cohort; disparities; integrase strand transfer inhibitors (INSTIs); transgender.

Grants and funding

R24 AI152598/AI/NIAID NIH HHS/United States